{"id":44114,"date":"2025-10-22T20:22:18","date_gmt":"2025-10-22T12:22:18","guid":{"rendered":"https:\/\/flcube.com\/?p=44114"},"modified":"2025-10-22T20:22:19","modified_gmt":"2025-10-22T12:22:19","slug":"bireoccilib-outperforms-traditional-cdk4-6-in-bright%e2%80%913-xuanzhu-biopharma-announces-interim-phase-iii-results-at-esmo-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44114","title":{"rendered":"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025"},"content":{"rendered":"\n<p><strong>Xuanzhu Biopharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2575:HKG\">HKG: 2575<\/a>)<\/strong> announced that the interim analysis of the <strong>Phase\u202fIII BRIGHT\u20113<\/strong> study demonstrates that <strong>bireociclib (trade name Xuan\u2011Yue\u2011Ning)<\/strong>, when combined with aromatase inhibitors letrozole or anastrozole, provides superior disease control for first\u2011line treatment of <strong>HR\u207a\/HER2\u2011<\/strong> advanced breast cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-findings\"><strong>Key Findings<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>End\u2011Point<\/th><th>Bireociclib\u202f+\u202fAI<\/th><th>AI Alone<\/th><\/tr><\/thead><tbody><tr><td><strong>Progression\u2011Free Survival (PFS)<\/strong><\/td><td>20.6\u202fmonths<\/td><td>14.3\u202fmonths<\/td><\/tr><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td>57.4\u202f%<\/td><td>41.2\u202f%<\/td><\/tr><tr><td><strong>\u2265 Grade\u202f3 Hematologic Toxicity<\/strong><\/td><td>12.1\u202f%<\/td><td>28.7\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Significant PFS benefit<\/strong> (+6.3\u202fmonths) with a <strong>modest safety profile<\/strong>.<\/li>\n\n\n\n<li><strong>Reduced hematologic toxicity<\/strong> compared with established CDK4\/6 agents.<\/li>\n\n\n\n<li><strong>Subgroup analysis<\/strong> confirms benefit across age, performance status, and prior endocrine exposure.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-bireociclib\"><strong>About Bireociclib<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel CDK2\/4\/6 inhibitor<\/strong> with a <strong>multi\u2011target synergistic mechanism<\/strong> that blocks tumor\u2011cell cycle progression while sparing normal hematopoiesis.<\/li>\n\n\n\n<li><strong>NMPA\u2011approved<\/strong> on May\u202f13\u202f2025 for:<\/li>\n\n\n\n<li>Combination with <strong>fulvestrant<\/strong> in endocrine\u2011therapy\u2011refractory disease.<\/li>\n\n\n\n<li><strong>Monotherapy<\/strong> in metastatic disease after \u22652 endocrine therapies + chemotherapy \u2013 the <strong>first and only CDK4\/6 monotherapy<\/strong> approved in China.<\/li>\n\n\n\n<li><strong>Global development<\/strong>: Phase\u202fIII BRIGHT\u20113 (first\u2011line HR\u207a\/HER2\u207b), Phase\u202fII BIRCH (second\u2011line), and Phase\u202fI\/II global trials underway.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\"><strong>Strategic Implications<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Positions Xuanzhu as a <strong>leader in CDK4\/6 oncology<\/strong> with a differentiated safety profile.<\/li>\n\n\n\n<li>Opens the <strong>monotherapy market<\/strong> in China, potentially expanding global reach.<\/li>\n\n\n\n<li>Enhances portfolio depth for <strong>first\u2011line endocrine\u2011plus\u2011CDK therapy<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase\u202fIII BRIGHT\u20113&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44116,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,16,17,4408,670],"class_list":["post-44114","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-cancer","tag-clinical-trial-results","tag-hkg-2575","tag-xuanzhu-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase\u202fIII BRIGHT\u20113 study demonstrates that bireociclib (trade name Xuan\u2011Yue\u2011Ning), when combined with aromatase inhibitors letrozole or anastrozole, provides superior disease control for first\u2011line treatment of HR\u207a\/HER2\u2011 advanced breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44114\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025\" \/>\n<meta property=\"og:description\" content=\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase\u202fIII BRIGHT\u20113 study demonstrates that bireociclib (trade name Xuan\u2011Yue\u2011Ning), when combined with aromatase inhibitors letrozole or anastrozole, provides superior disease control for first\u2011line treatment of HR\u207a\/HER2\u2011 advanced breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44114\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T12:22:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-22T12:22:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2207.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\\\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025\",\"datePublished\":\"2025-10-22T12:22:18+00:00\",\"dateModified\":\"2025-10-22T12:22:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114\"},\"wordCount\":241,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2207.webp\",\"keywords\":[\"Academic conference\",\"Cancer\",\"Clinical trial results\",\"HKG: 2575\",\"Xuanzhu Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44114#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44114\",\"name\":\"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\\\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2207.webp\",\"datePublished\":\"2025-10-22T12:22:18+00:00\",\"dateModified\":\"2025-10-22T12:22:19+00:00\",\"description\":\"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase\u202fIII BRIGHT\u20113 study demonstrates that bireociclib (trade name Xuan\u2011Yue\u2011Ning), when combined with aromatase inhibitors letrozole or anastrozole, provides superior disease control for first\u2011line treatment of HR\u207a\\\/HER2\u2011 advanced breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44114\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2207.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2207.webp\",\"width\":1080,\"height\":608,\"caption\":\"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\\\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44114#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\\\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase\u202fIII BRIGHT\u20113 study demonstrates that bireociclib (trade name Xuan\u2011Yue\u2011Ning), when combined with aromatase inhibitors letrozole or anastrozole, provides superior disease control for first\u2011line treatment of HR\u207a\/HER2\u2011 advanced breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44114","og_locale":"en_US","og_type":"article","og_title":"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025","og_description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase\u202fIII BRIGHT\u20113 study demonstrates that bireociclib (trade name Xuan\u2011Yue\u2011Ning), when combined with aromatase inhibitors letrozole or anastrozole, provides superior disease control for first\u2011line treatment of HR\u207a\/HER2\u2011 advanced breast cancer.","og_url":"https:\/\/flcube.com\/?p=44114","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-22T12:22:18+00:00","article_modified_time":"2025-10-22T12:22:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2207.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44114#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44114"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025","datePublished":"2025-10-22T12:22:18+00:00","dateModified":"2025-10-22T12:22:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44114"},"wordCount":241,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44114#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2207.webp","keywords":["Academic conference","Cancer","Clinical trial results","HKG: 2575","Xuanzhu Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44114#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44114","url":"https:\/\/flcube.com\/?p=44114","name":"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44114#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44114#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2207.webp","datePublished":"2025-10-22T12:22:18+00:00","dateModified":"2025-10-22T12:22:19+00:00","description":"Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase\u202fIII BRIGHT\u20113 study demonstrates that bireociclib (trade name Xuan\u2011Yue\u2011Ning), when combined with aromatase inhibitors letrozole or anastrozole, provides superior disease control for first\u2011line treatment of HR\u207a\/HER2\u2011 advanced breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44114#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44114"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44114#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2207.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2207.webp","width":1080,"height":608,"caption":"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44114#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4\/6 IN BRIGHT\u20113: Xuanzhu Biopharma Announces Interim Phase\u202fIII Results at ESMO 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2207.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44114"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44114\/revisions"}],"predecessor-version":[{"id":44117,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44114\/revisions\/44117"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44116"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}